7月15日恒生指数上涨1.60%，报收24590.12点，全天南向资金通过港股通渠道合计净买入38.24亿港 元。 代码简称类型成交金额 证券时报•数据宝统计，7月15日港股通全天合计成交金额为1507.55亿港元，成交净买入38.24亿港元。 具体来看，沪市港股通成交金额966.83亿港元，成交净买入15.90亿港元；深市港股通成交金额540.72亿 港元，成交净买入22.34亿港元。 成交活跃股方面，沪市港股通前十大成交活跃股中，阿里巴巴-W成交额为75.09亿港元，成交金额居 首；其次是美团-W、腾讯控股，成交金额分别为38.52亿港元、37.38亿港元。以净买卖金额统计，腾讯 控股净买入额为1.31亿港元，净买入金额居首，该股收盘股价上涨3.50%。净卖出金额最多的是中芯国 际，净卖出5.09亿港元，收盘股价下跌1.83%。 深市港股通前十大成交活跃股中，成交额居首的是阿里巴巴-W，成交金额40.83亿港元；其次是腾讯控 股、美团-W，成交金额分别为28.49亿港元、24.63亿港元。以净买卖金额统计，有8只股为净买入，净 买入金额最多的是美团-W，净买入5.62亿港元，该股收盘上涨4.38%。净卖出 ...

Core Insights - On July 15, 2025, Alibaba-W (09988), Meituan-W (03690), and Tencent Holdings (00700) were the top three companies by trading volume in the southbound trading of the Stock Connect, with trading amounts of 75.09 billion, 38.52 billion, and 37.38 billion respectively [1] - In the southbound trading of the Shenzhen-Hong Kong Stock Connect, Alibaba-W (09988), Tencent Holdings (00700), and Meituan-W (03690) also ranked as the top three, with trading amounts of 40.83 billion, 28.49 billion, and 24.63 billion respectively [1] Southbound Trading Activity - The top active companies in the southbound trading of the Shanghai-Hong Kong Stock Connect included: - Alibaba-W (09988) with a trading amount of 75.09 billion and a net buy of -4.77 billion - Meituan-W (03690) with a trading amount of 38.52 billion and a net buy of +843.695 million - Tencent Holdings (00700) with a trading amount of 37.38 billion and a net buy of +1.31 billion [2] - The top active companies in the southbound trading of the Shenzhen-Hong Kong Stock Connect included: - Alibaba-W (09988) with a trading amount of 40.83 billion and a net buy of +4.75 billion - Tencent Holdings (00700) with a trading amount of 28.49 billion and a net buy of -9.62 billion - Meituan-W (03690) with a trading amount of 24.63 billion and a net buy of +5.62 billion [2]

Group 1 - The Hang Seng Healthcare Index (HSHCI) increased by 0.87% as of July 15, 2025, with notable gains from stocks such as Health Road (02587) up 9.58% and BeiGene (06160) up 5.18% [3] - The Hang Seng Healthcare ETF (513060) has seen a 1.01% rise, marking its third consecutive increase, with a latest price of 0.6 yuan [3] - The ETF's trading volume was active, with a turnover of 1.151 billion yuan and a turnover rate of 13.96% [3] Group 2 - The adjustment of the 2025 National Basic Medical Insurance and commercial health insurance drug catalogues officially started on July 11, 2025, with results expected to be announced between October and November 2025 [4] - In the first half of 2025, China's innovative drug license-out transactions reached nearly 66 billion USD, surpassing the total for 2024, indicating strong interest from multinational pharmaceutical companies [4] - Key transaction categories include Antibody-Drug Conjugates (ADC) and bispecific antibodies, with expectations for continued activity in the second half of 2025 [4] Group 3 - The Hang Seng Healthcare ETF's size grew by 196 million yuan over the past week, ranking it in the top third among comparable funds [5] - The ETF's net value has increased by 19.77% over the past two years, with a maximum monthly return of 28.34% since inception [5] - The ETF's Sharpe ratio for the past year is 2.02, indicating strong risk-adjusted returns [5] Group 4 - The management fee for the Hang Seng Healthcare ETF is 0.50%, and the custody fee is 0.15% [6] - The ETF's tracking error over the past year is 0.060%, the highest tracking precision among comparable funds [6] - The latest price-to-earnings ratio (PE-TTM) for the index tracked by the ETF is 28.79, indicating a valuation lower than 87.88% of the time over the past three years [6] Group 5 - The top ten weighted stocks in the Hang Seng Healthcare Index account for 58.84% of the index, including companies like Innovent Biologics (01801) and WuXi Biologics (02269) [6]

Market Overview - On July 14, the Hang Seng Index rose by 64 points or 0.3%, closing at 24,203 points, with a daily trading range of only 167 points[1] - The Hang Seng Tech Index increased by 0.7%, closing at 5,283 points, while total market turnover decreased to HKD 210.4 billion[1] - Net inflow from the Hong Kong Stock Connect was HKD 8.2 billion, indicating a positive sentiment despite the lack of clear direction in the market[1] Sector Performance - The biopharmaceutical sector showed strong performance, with 3SBio (1530 HK) rising by 12.2% and BGI Genomics (6955 HK) increasing by 22.3%[1] - The chemical, paper, copper, and other non-ferrous metal sectors benefited from "capacity reduction" policies, contributing to their positive performance[1] - AI and robotics-related stocks, previously lagging, saw gains, with Kingsoft Cloud (3896 HK) and GDS Holdings (9698 HK) rising between 2.9% and 8.5%[1] Macroeconomic Insights - In June, China's M1 money supply grew by 4.6%, the fastest rate since May 2023, while M2 increased by 8.3%, the highest since March 2024[2] - Social financing in June increased by CNY 900 billion, with government bonds contributing CNY 500 billion to this growth[2] - New home sales in major cities fell by 26.5% year-on-year, indicating a downturn in the real estate market[2] Industry Developments - 361 Degrees (1361 HK) reported a 10% year-on-year growth in retail sales for its main brand and children's clothing, with online sales up by approximately 20%[3] - Sai Jing Technology (580 HK) announced a CNY 180 million acquisition of Hunan Hong'an's equity, which is expected to enhance its supply chain and customer resources[3] - The pharmaceutical sector rose by 2.1%, driven by expectations of new drug listings in the national insurance catalog for 2025[4] Future Projections - Tianlun Gas (1600 HK) is expected to return to profit growth starting FY25, with a projected CAGR of 12.0% from FY24 to FY27[6] - The global autonomous driving market is projected to reach USD 207.4 billion in 2024, growing at a CAGR of 31.0% until 2027[13] - China's autonomous driving market is expected to grow from CNY 330 billion in 2023 to CNY 791.5 billion by 2027, with a CAGR of 24.4%[13]

（文章来源：证券时报网） 昊天国际建投、国联民生、老铺黄金、博安生物为近一个月首次上榜，昊天国际建投当日港股通成交额 为16.21亿港元，成交净买入1.06亿港元，该股当日收盘下跌32.78%。国联民生当日港股通成交额为 16.87亿港元，成交净买入0.23亿港元，该股当日收盘上涨10.90%。老铺黄金当日港股通成交额为10.15 亿港元，成交净卖出3.65亿港元，该股当日收盘下跌2.67%。博安生物当日港股通成交额为13.84亿港 元，成交净买入0.51亿港元，该股当日收盘上涨22.31%。 7月14日港股通成交活跃股榜单 | 证券 | 证券简称 | 成交金额（亿 | 净买入金额（亿 | 近一个月上榜 | 最新收盘价 | 日涨跌幅 | | --- | --- | --- | --- | --- | --- | --- | | 代码 | | 港元） | 港元） | 次数 | （港元） | （%） | | 00700 | 腾讯控股 | 15.26 | -0.84 | 20 | 500.000 | 0.68 | | 01810 | 小米集团 W | 26.75 | -0.66 | 20 | 57.300 | -0 ...

Core Insights - On July 14, 2025, Guotai Junan International (01788), Legend Holdings (06683), and Alibaba-W (09988) were the top three companies by trading volume in the Southbound Stock Connect, with trading amounts of 39.23 billion, 19.38 billion, and 18.37 billion respectively [1] - In the Shenzhen-Hong Kong Stock Connect, Alibaba-W (09988), Guotai Junan International (01788), and Tencent Holdings (00700) led the trading volume, with amounts of 18.33 billion, 15.70 billion, and 15.26 billion respectively [1] Southbound Stock Connect Top Active Companies - Guotai Junan International (01788) had a trading amount of 39.23 billion with a net buying amount of +18.74 million [2] - Legend Holdings (06683) recorded a trading amount of 19.38 billion with a net buying amount of +53.64 million [2] - Alibaba-W (09988) achieved a trading amount of 18.37 billion with a net buying amount of +223 million [2] - Health Road (02587) had a trading amount of 17.86 billion with a net selling amount of -66.69 million [2] - Other notable companies included Guolian Minsheng (01456) with 16.87 billion and a net buying amount of +23.39 million, and Meituan-W (03690) with 16.20 billion and a net buying amount of +783 million [2] Shenzhen-Hong Kong Stock Connect Top Active Companies - Alibaba-W (09988) led with a trading amount of 18.33 billion and a net buying amount of +636 million [2] - Guotai Junan International (01788) followed with a trading amount of 15.70 billion and a net buying amount of +72.43 million [2] - Tencent Holdings (00700) had a trading amount of 15.26 billion but recorded a net selling amount of -842.80 million [2] - Other significant companies included Xiaomi Group-W (01810) with 12.92 billion and a net selling amount of -1.01 billion, and Meituan-W (03690) with 12.69 billion and a net buying amount of +440 million [2]

Summary of Key Points Core Viewpoint - On July 14, southbound funds recorded a transaction volume of HKD 1216.88 billion, with a net inflow of approximately HKD 82.43 billion, indicating strong investor interest in Hong Kong stocks [1]. Group 1: Net Inflows - Major net purchases included Meituan-W (03690.HK) with HKD 1.22 billion, Alibaba-W (09988.HK) with HKD 859 million, and SMIC (00981.HK) with HKD 300 million [1]. - Meituan-W saw a price increase of 0.75%, with net inflows of HKD 783 million from the Shanghai-Hong Kong Stock Connect and HKD 440 million from the Shenzhen-Hong Kong Stock Connect [1]. - Alibaba-W experienced a price rise of 0.95%, with net inflows of HKD 223 million from the Shanghai-Hong Kong Stock Connect and HKD 636 million from the Shenzhen-Hong Kong Stock Connect [1]. - SMIC's stock price increased by 1.09%, with net inflows of HKD 300 million from the Shenzhen-Hong Kong Stock Connect [1]. Group 2: Net Outflows - Significant net sales were observed in Old Puhuang (06181.HK) with HKD 364.90 million, Health Road (02587.HK) with HKD 129.49 million, Tencent Holdings (00700.HK) with HKD 84.28 million, and Xiaomi Group W (01810.HK) with HKD 65.71 million [1]. - Old Puhuang's stock price declined by 2.67%, reflecting the net outflow [4]. - Health Road's stock price increased by 13.60%, despite the net outflow of HKD 66.70 million from the Shanghai-Hong Kong Stock Connect and HKD 62.80 million from the Shenzhen-Hong Kong Stock Connect [4]. - Tencent Holdings saw a price increase of 0.68%, with net outflows of HKD 84.28 million from the Shenzhen-Hong Kong Stock Connect [4]. - Xiaomi Group W's stock price decreased by 0.09%, with net inflows of HKD 35.12 million from the Shanghai-Hong Kong Stock Connect but net outflows of HKD 100.82 million from the Shenzhen-Hong Kong Stock Connect [4]. Group 3: Other Notable Movements - Innovent Biologics (01801.HK) saw a price increase of 1.80%, with net inflows of HKD 160 million from the Shenzhen-Hong Kong Stock Connect [2]. - Haotian International Investment (01341.HK) experienced a significant drop of 32.78%, despite net inflows of HKD 106 million from the Shanghai-Hong Kong Stock Connect [3]. - Guotai Junan International (01788.HK) saw a slight decline of 0.16%, with net inflows of HKD 18.74 million from the Shanghai-Hong Kong Stock Connect and HKD 72.43 million from the Shenzhen-Hong Kong Stock Connect [4].

南向资金今日大幅净买入82.43亿元。港股通（沪）方面，美团-W、阿里巴巴-W分别获净买入7.83亿港 元、2.23亿港元；健康之路净卖出额居首，金额为0.67亿港元；港股通（深）方面，阿里巴巴-W、美 团-W分别获净买入6.36亿港元、4.4亿港元；老铺黄金净卖出额居首，金额为3.65亿港元。 ...

Company Overview - Health Road Holdings Limited operates a digital health service platform in China and is the fourth largest digital health service platform by registered personal users as of December 31, 2023 [2] - The company is also the fifth largest digital health service platform by revenue for the year 2023 [2] - Since 2001, the company has provided health services to individual users on its digital platform and expanded to offer enterprise services and digital marketing since 2015 [2] Financial Performance - As of December 31, 2024, the company reported total revenue of 1.201 billion yuan, a year-on-year decrease of 3.51% [1] - The net profit attributable to shareholders was -268 million yuan, an increase of 13.42% year-on-year [1] - The gross profit margin stood at 30.47%, with a debt-to-asset ratio of 59.82% [1] Market Performance - As of July 14, the stock price of Health Road was 8.77 HKD per share, reflecting a 13.6% increase with a trading volume of 216 million shares and a turnover of 1.831 billion HKD [1] - Over the past month, the stock has experienced a cumulative decline of 86.59%, and a year-to-date decline of 40.98%, underperforming the Hang Seng Index by 20.34% [1] Industry Valuation - The average price-to-earnings (P/E) ratio for the healthcare equipment and services industry is -2.89 times, with a median of 1.17 times [1] - Health Road's P/E ratio is -23.37 times, ranking 68th in the industry [1] - Other companies in the industry have P/E ratios such as Giant Star Medical Holdings at 0.28 times, Jingjiu Health at 0.38 times, and others ranging from 1.96 to 5.45 times [1] Analyst Ratings - Liao Asset Management has given a "Buy" rating for Health Road, with a target price of 68.5 HKD [1]

Group 1 - Recent southbound capital inflow has surged, with a net purchase of 26.3 billion HKD in one week, an increase of nearly 90% compared to the previous week, and total trading volume exceeding 680 billion HKD [1][3] - The People's Bank of China announced an expansion of the southbound bond connect quota to 1 trillion HKD, allowing more institutional participation, which is seen as a significant boost for Hong Kong stocks [3] - The trend of capital flow is influenced by the acceleration of the internationalization of the RMB, indicating that smart money is positioning itself ahead of market movements [3] Group 2 - Health Road, a leading digital health platform in China, has seen its shares increased to 24.24 million, accounting for 2.75% of total shares, driven by rising health awareness and online medical demand [3] - China Spring, a hidden champion in the private higher education sector, has over 100,000 students across five universities and has aligned its curriculum with market needs, benefiting from government policies promoting digital education [3] - Contemporary Amperex Technology Co., Ltd. (CATL), a global leader in power batteries, has experienced a premium rate increase to 46%, attributed to a deepened cooperation agreement with Geely and significant stock purchases by major investment firms [4] Group 3 - Heng Rui Pharmaceutical has made advancements in breast cancer treatment with its oral estrogen receptor degrader HRS-8080 entering phase III clinical trials, positioning it among the global leaders in this field [4] - Superstar Legend has seen a surge in stock price following Jay Chou's entry into Douyin, with a net purchase of 416 million HKD, reflecting the revaluation of celebrity IP commercial value [4]